Alumis Inc.
ALMS
Kedudukan dalam Saham
#10157
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Harga Saham
$6.41
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$830.25M
Perubahan (1 hari)
4.81%
Perubahan (1 tahun)
182.57%
Negara
US
Perdagangan Alumis Inc. (ALMS)
Kategori
Healthcare
Nisbah P/S bagi Alumis Inc. (ALMS)
Nisbah P/S pada October 2026 TTM: 0.00
Menurut laporan kewangan dan harga saham terkini Alumis Inc., nisbah P/S semasa (TTM) ialah 0.00. Pada akhir 2023, nisbah P/S syarikat ialah 0.00.
Sejarah nisbah P/S untuk Alumis Inc. dari 2021 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
